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A B S T R A C T
Background
Fetal fibronectin (FFN) is an extracellular matrix glycoprotein localized at the maternal-fetal interface of the amniotic membranes,
between chorion and decidua, where it is concentrated in this area between decidua and trophoblast. In normal conditions, FFN is
found at very low levels in cervicovaginal secretions. Levels greater than or equal to 50 ng/mL at or after 22 weeks have been associated
with an increased risk of spontaneous preterm birth. In fact, FFN is one of the best predictors of preterm birth in all populations studied
so far, and can help in selecting which women are at significant risk for preterm birth. This is an update of a review first published in
2008.
Objectives
To assess the effectiveness of management based on knowledge of FFN testing results for preventing preterm birth.
Search methods
For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register (7 September 2018), ClinicalTrials.gov, the WHO
International Clinical Trials Registry Platform (ICTRP) (7 September 2018), and reference lists of retrieved studies.
Selection criteria
Randomized controlled trials of pregnant women screened with FFN for risk of preterm birth. Studies included are based exclusively
on knowledge of FFN results versus no such knowledge, and we have excluded studies including women with only positive or only
negative FFN results.
Data collection and analysis
Two review authors independently assessed trials for inclusion and risk of bias, extracted data, and checked them for accuracy. The
quality of the evidence was assessed using the GRADE approach.
Main results
We identified 16 trials, of which six were eligible for inclusion. The six included studies randomized 546 women with singleton
gestations and threatened preterm labor (PTL) at 23 0/7 to 34 6/7 weeks. A total of 277 women were randomized to knowledge and
269 to no knowledge of FFN. No trials were identified on asymptomatic women or multiple gestations.
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The risk of bias of included studies was mixed. For selected important outcomes, preterm birth before 37, 34, and 32 weeks, and
maternal hospitalization, we graded the quality of the evidence and created a ’Summary of findings’ table. For these outcomes, the
evidence was graded as mainly low quality due to the imprecision of effect estimates.
Management based on knowledge of FFN results may reduce preterm birth before 37 weeks (21.6%) versus controls without such
knowledge (29.2%) (risk ratio (RR) 0.72, 95% confidence interval (CI) 0.52 to 1.01; 4 trials; 357 women; low-quality evidence).
However, management based on knowledge of FFN results may make little or no difference to preterm birth before 34 (RR 1.09, 95%
CI 0.54 to 2.18; 4 trials; 357 women; low-quality evidence) or maternal hospitalization (RR 1.06, 95% CI 0.79 to 1.43; 5 trials; 441
women; low-quality evidence). The evidence for preterm birth before 32 weeks is uncertain because the quality was found to be very
low (average RR 0.79, 95% CI 0.16 to 3.96; 4 trials; 357 women; very low-quality evidence).
For all other outcomes, for which there were available data (preterm birth less than 28 weeks; gestational age at delivery (weeks);
birthweight less than 2500 g; perinatal death; tocolysis; steroids for fetal lung maturity; time to evaluate; respiratory distress syndrome;
neonatal intensive care unit (NICU) admission; and NICU days), knowledge of FFN results may make little or no difference to the
outcomes.
Authors’ conclusions
The evidence from this review suggests that management based on knowledge of FFN results may reduce preterm birth before 37 weeks.
However, our confidence in this result is limited as the evidence was found to be of low quality. Effects on other substantive outcomes
are uncertain due to serious concerns in study design, inconsistency, and imprecision of effect estimates. No trials were identified on
asymptomatic women, or multiple gestations.
Future studies are needed that include specific populations (e.g. singleton gestations with symptoms of preterm labor), a study group
managed with a protocol based on the FFN results, and that report not only maternal but also important perinatal outcomes. Cost-
effectiveness analyses are also needed.
P L A I N L A N G U A G E S U M M A R Y
Fetal fibronectin testing for reducing the risk of preterm birth
What is the issue?
To assess the effectiveness of management of pregnant women based on a knowledge of fetal fibronectin test results for preventing
preterm birth, compared with not having that knowledge. Fetal fibronectin (FFN) acts as a ‘glue’ between the pregnancy and the uterus.
Normally very low levels of FFN can be found in secretions of the vagina and cervix. Raised levels at or after 22 weeks have been
associated with an increased risk of spontaneous preterm birth.
Why is this important?
Preterm birth before 37 weeks is the main cause of sickness and death for newborn infants. Most women who give birth preterm have
preterm labor symptoms such as contractions but many of the women with symptoms go on to deliver at term (37 weeks or more).
Fetal fibronectin (FFN) is a test that can identify the women with symptoms of preterm labor who are most at risk for preterm birth.
The level of FFN is measured in secretions from the vagina or cervix.
What evidence did we find?
We found six randomised controlled studies involving 546 women who were pregnant with one baby and were showing signs of preterm
labor at between 23 to 34 weeks’ gestation. We graded the following evidence as mainly low quality because of the low number of
women in the studies and a wide variation in findings. We found that the number of births before 37 weeks may be slightly reduced
when women and their doctors know the results of the FFN test (21.6% versus 29.2%; 4 trials; 357 women). However, knowledge of
FFN results may make little or no difference for the other outcomes with available data, including: maternal hospitalization (5 trials;
441 women); use of uterine relaxants (tocolysis) to try to prevent labor; earlier preterm births; women’s gestational age at delivery;
babies with a birthweight less than 2500 g; newborn deaths; the number of babies with respiratory distress syndrome; giving steroids
to mature the unborn babies’ lungs; and number of days in a neonatal intensive care unit (NICU).
What does this mean?
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This review of six studies did not find enough evidence to say whether or not the FFN test should be used in the management of
women showing signs of preterm labor. A screening test such as FFN can only be considered effective if interventions based on the
screening results, such as giving drugs to relax the uterus, reduce the number of preterm births. Further research should be encouraged.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
FFN knowledge versus no knowledge in reducing the risk of preterm birth
Patient or population: women with singleton pregnancies and threatened preterm labor (PTL) between 23 to 35 weeks
Setting: hospital sett ings in United Kingdom and United States
Intervention: FFN knowledge
Comparison: no knowledge
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no knowledge Risk with FFN knowl-
edge
Preterm birth < 37
weeks
Study populat ion RR 0.72
(0.52 to 1.01)
434
(5 RCTs)
⊕⊕©©
LOW 12
292 per 1.000 211 per 1.000
(152 to 295)
Preterm birth < 34
weeks
Study populat ion RR 1.09
(0.54 to 2.18)
357
(4 RCTs)
⊕⊕©©
LOW 13
79 per 1.000 86 per 1.000
(43 to 172)
Preterm birth < 32
weeks
Study populat ion Average RR 0.79
(0.16 to 3.96)
357
(4 RCTs)
⊕©©©
VERY LOW 45
56 per 1.000 36 per 1.000
(14 to 98)
Maternal hospitaliza-
t ion
Study populat ion RR 1.06
(0.79 to 1.43)
441
(5 RCTs)
⊕⊕©©
LOW 13
268 per 1.000 284 per 1.000
(211 to 383)
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io; OR: odds rat io;
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 We downgraded (1) level for serious lim itat ions in study design due to some studies having unclear risk of bias for several
domains and one study being at high risk of detect ion bias
2 We downgraded (1) level for serious imprecision due to wide CI just crossing the line of no ef fect
3 We downgraded (1) level for serious imprecision due to wide CI crossing the line of no ef fect
4 We downgraded (2) levels for very serious imprecision due to wide CI crossing the line of no ef fect and a small number of
events
5 We downgraded (1) level for serious inconsistency due to evidence of stat ist ical heterogeneity I2 = 46%
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B A C K G R O U N D
Description of the condition
Preterm birth is defined by the World Health Organization
(WHO) as birth between 20 and 36 6/7 weeks. Its incidence is
about 5% to 12% in most low-, middle-, and high-income coun-
tries. This incidence is increasing in many countries, including
low-income countries.
Preterm birth is the main cause of neonatal morbidity and mortal-
ity inmost countries, especially in high- andmiddle-income coun-
tries. In the USA, 75% of perinatal mortality occurs in preterm
babies; more than two-thirds of perinatal mortality (60% of total)
occurs in infants born at less than 32 weeks. Mortality and mor-
bidity are inversely associated with gestational age at birth. Mor-
bidities include respiratory distress syndrome, bronchopulmonary
dysplasia, intraventricular haemorrhage, necrotizing enterocolitis,
sepsis, retinopathy, etc. All members of a family inwhich a preterm
birth occurs suffer greatly, in several aspects, including medically,
socially, psychologically, and financially (Berghella 2016).
Description of the intervention
Fetal fibronectin is an extracellular matrix glycoprotein. Fetal fi-
bronectin in biologic fluids is produced by amniocytes and by cy-
totrophoblast. It is present throughout gestation in all pregnan-
cies. It is not subject to genetic polymorphism. There are very high
levels in amniotic fluid (100 µg/mL) in the second trimester, and
30 µg/mL at term. It is localized at the maternal-fetal interface
of the amniotic membranes, between chorion and decidua, where
it is concentrated in this area between decidua and trophoblast.
Here it acts as a ’glue’ between the pregnancy and the uterus.
Concentration of fetal fibronectin protein found in blood is 1/5th
that found in amniotic fluid; it is not present in urine. In normal
conditions, this glycoprotein remains in this area between chorion
and decidua, and very low levels are found in cervicovaginal secre-
tions after 22 weeks (less than 50 ng/mL). Levels above this value
(greater than or equal to 50 ng/mL) at or after 22 weeks in the
cervicovaginal secretions collected by a swab have been associated
with an increased risk of spontaneous preterm birth (Berghella
2016).
The fetal fibronectin test assesses risk of preterm birth by measur-
ing amount of fetal fibronectin in cervicovaginal secretions. In fact,
fetal fibronectin is one of the best predictors of preterm birth in all
populations studied so far, including low- and high-risk women
without preterm labor, twins, andwomen inpreterm labor (Leitich
1999). The overall sensitivity and specificity are 56% and 84% for
preterm before 37 weeks, respectively, but vary according to gesta-
tional age at collection, population studied, prevalence of preterm
birth, single versus multiple screening, etc. (Leitich 1999). Its pos-
itive predictive value varies from about 9% to 46% depending on
the incidence of preterm labor in the population studies (Leitich
1999). Even at 13 to 22 weeks, higher (using 90th percentile) fetal
fibronectin levels are associated with a two- to three-fold increase
risk in subsequent spontaneous preterm labor.
How the intervention might work
The majority of women presenting with symptoms of preterm
labor, such as contractions, back pain, and increase in discharge,
do not deliver preterm. Fetal fibronectin has been shown to pre-
dict which women would deliver preterm among those presenting
with symptoms of preterm labor (threatened preterm labor). By
predicting better which women to target interventions such as to-
colysis on, fetal fibronectin screening of women with threatened
preterm labor could decrease the incidence of preterm birth.
Why it is important to do this review
Preterm birth remains one of the main problems in obstetrics,
given its association with perinatal morbidity and mortality, and
high costs to care for these sick neonates. Half of preterm birth
is preceded by preterm labor. The management of women with
threatened preterm labor is controversial, with great difficulty
in identifying the subgroup (about 30%) of women presenting
with this condition who indeed deliver preterm. Being able to
show that screening with fetal fibronectin decreases preterm birth
would contribute to potentially save and/or ameliorate millions of
lives of neonates worldwide every year. On the contrary, should
this study show no benefit from fetal fibronectin screening, this
screening, currently used in many units around the world, could
be stopped, resulting in significant savings in time and money
(Berghella 2016). This is an update of a review first published in
2008.
O B J E C T I V E S
To assess the effectiveness of management based on knowledge of
FFN testing results for preventing preterm birth.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Published and unpublished randomized and quasi-randomized
controlled trials. Cluster-randomized trials were also eligible for
inclusion, though none were identified for this update. Abstracts
were eligible for inclusion if sufficient information was provided
to judge the quality and potential for bias of these trials.
Types of participants
Pregnant women between the gestational ages of 22 and 34 weeks
screened with fetal fibronectin for risk of preterm birth.
Types of interventions
A screening test such as fetal fibronectin can only be considered
effective if interventions based on fetal fibronectin screening results
reduce the outcome of preterm birth. Interventions based on fetal
fibronectin screening results can also be classified as:
1. interventions based on knowledge of fetal fibronectin results
(e.g. fetal fibronectin is collected on all women, but women are
randomized so that in 50% of them the result is available to
them and the managing obstetrician, while in 50% the fetal
fibronectin is blind to them and the managing obstetrician; or
fetal fibronectin screening is done only on half of the women);
2. interventions based on positive fetal fibronectin;
3. interventions based on negative fetal fibronectin.
This review focuses exclusively on (1), i.e. interventions based on
knowledge of fetal fibronectin results.
Types of outcome measures
Primary outcomes
(1) Preterm birth (less than 37 weeks)
Secondary outcomes
(2) Preterm birth less than 34 weeks
(3) Preterm birth less than 32 weeks
(4) Preterm birth less than 28 weeks
(5) Gestational age at delivery
(6) Birthweight less than 2500 g
(7) Perinatal death (fetal death and neonatal death)
(8) Maternal hospitalization
(9) Tocolysis
(10) Steroids for fetal maturity
(11) Time to evaluate (time from arrival to hospital for evaluation
of preterm labor to decision regarding admission, discharge, or
extended monitoring)
(12) Respiratory distress syndrome
(13) Intraventricular haemorrhage
(14) Necrotizing enterocolitis
(15) Sepsis
(16) Neonatal intensive care unit (NICU) admission
(17) NICU days
(18) Maternal well-being (e.g. stress level, etc.)
(19) Economic analysis (cost-effectiveness, cost utility)
We will report outcomes 1, 2, 3, 4, 5, 8, 9, 10, 11, 18, and 19 with
’mothers’ as the denominator. We will report outcomes 6, 7, 12,
13, 14, 15, 16, and 17 with ’fetuses/neonates’ as the denominator.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
For this update, we searched Cochrane Pregnancy and Child-
birth’s Trials Register by contacting their Information Specialist (7
September 2018).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. It represents
over 30 years of searching. For full current search methods used
to populate Pregnancy and Childbirth’s Trials Register including
the detailed search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL; the list of handsearched journals and confer-
ence proceedings; and the list of journals reviewed via the current
awareness service; please follow this link.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches the
Register for each review using this topic number rather than key-
words. This results in a more specific search set that has been fully
accounted for in the relevant review sections (Included studies;
Excluded studies; Ongoing studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform ( ICTRP) for unpub-
lished, planned and ongoing trial reports (7 September 2018) us-
ing the search methods detailed in Appendix 1.
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Searching other resources
We reviewed the reference list of all articles, in particular trials and
review articles. We contacted all researchers of included trials to
provide actual databases and any pertinent further information.
We contacted experts in the field for additional and ongoing trials.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Berghella 2008.
For this update, the following methods were used for assessing the
two trials that were identified as a result of the updated search.
Selection of studies
The two review authors independently assessed for inclusion all
the potential studies identified as a result of the search strategy.We
resolved any disagreement through discussion. VincenzoBerghella
is a co-author on one of the excluded trials (Ness 2007) and was
not involved in the eligibility assessment for this trial as this was
assessed by Gabriele Saccone.
Data extraction and management
We designed a form to extract data. For eligible studies, the two
authors extracted the data using the agreed form. We resolved
discrepancies through discussion. Data were entered into Review
Manager software (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
The two authors independently assessed risk of bias for each study
using the criteria outlined in theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Any disagreement was
resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomized participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
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• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomization);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we planned to
assess the likely magnitude and direction of the bias and whether
we considered it is likely to impact on the findings.
Assessment of the quality of the evidence using the
GRADE approach
For this update, the quality of the evidence was assessed using
the GRADE approach as outlined in the GRADE handbook in
order to assess the quality of the body of evidence relating to the
following outcomes for the main comparison (FFN knowledge
versus no knowledge):
1. Preterm birth < 37 weeks
2. Preterm birth < 34 weeks
3. Preterm birth < 32 weeks
4. Maternal hospitalization
GRADEproGuidelineDevelopmentTool was used to import data
from Review Manager 5.3 (RevMan 2014) in order to create a
’Summary of findings’ table. A summary of the intervention ef-
fect and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness, and publication bias) to assess the qual-
ity of the body of evidence for each outcome. The evidence can
be downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency, im-
precision of effect estimates, or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean difference if outcomes were measured in the
same way between trials. In future updates, if necessary, we will use
the standardised mean difference to combine trials that measured
the same outcome, but use different methods.
Unit of analysis issues
Cluster-randomized trials
We planned to include cluster-randomized trials in the analyses
along with individually-randomized trials, however all included
studies were individually-randomized trials.
Cross-over trials
We planned to exclude cross-over trials. However, no cross-over
trials were found during the search process.
Dealing with missing data
For included studies, levels of attrition were noted. In future up-
dates, if more eligible studies are included, the impact of including
studies with high levels of missing data in the overall assessment
of treatment effect will be explored by using sensitivity analysis.
For all outcomes, analyses were carried out, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partici-
pants randomized to each group in the analyses. The denominator
for each outcome in each trial was the number randomized minus
any participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if I² was greater than 30% and either Tau² was greater than
zero, or there was a low P value (less than 0.10) in the Chi² test for
heterogeneity. If we identified substantial heterogeneity (I² above
30%), we planned to explore it by prespecified subgroup analysis.
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Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar.
If there was clinical heterogeneity sufficient to expect that the un-
derlying treatment effects differed between trials, or if substan-
tial statistical heterogeneity was detected, we used random-effects
meta-analysis to produce an overall summary if an average treat-
ment effect across trials was considered clinically meaningful. The
random-effects summary will be treated as the average range of
possible treatment effects and we will discuss the clinical implica-
tions of treatment effects differing between trials. If the average
treatment effect is not clinically meaningful, we will not combine
trials. If we used random-effects analyses, the results were pre-
sented as the average treatment effect with 95% confidence inter-
vals, and the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
Hadwe identified substantial heterogeneity, we planned to investi-
gate it using subgroup analyses and to consider whether an overall
summary was meaningful, and if it was, to use a random-effects
analysis to produce it.
We planned to restrict subgroup analyses to primary outcomes for
the following subgroups:
1. Symptomatic women with threatened preterm labor versus
asymptomatic women
2. Women with multiple gestations versus women with
singleton gestations
We also planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2014) and to report the results
of subgroup analyses quoting the Chi² statistic and P value, and
the interaction test I² value.
Given that all included trials enrolled only singleton gestations
with threatened preterm labor, no subgroup analyses were per-
formed.
Sensitivity analysis
We carried out sensitivity analyses for the primary outcome to
explore the impact of trial quality assessed by concealment of al-
location, high attrition rates, or both. Poor-quality studies were
excluded from the analyses in order to assess whether this made
any difference to the overall result.
R E S U L T S
Description of studies
Results of the search
See: Figure 1
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Figure 1. Study flow diagram.
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For this update, we identified nine trial reports to assess. We in-
cluded two new trials (Dutta 2011; Lee 2013) (four reports). We
excluded two new trials (Gallot 2018; Osório 2010) (two reports)
and added one trial report to ongoing (NCT01431885) (one re-
port). Two reports were additional reports for two excluded trials
(Ness 2007; Shennan 2006). One trial previously included has
been excluded in this update (Ness 2007).
All women in the included studies had singleton gestations with
threatened preterm labor (PTL) between 22 and 34 weeks. There
were no trials comparing knowledge to no knowledge of fetal fi-
bronectin (FFN) in asymptomatic women or women with multi-
ple gestations. We identified no quasi-randomized trials.
Included studies
The six included studies randomized 546 women, of which 277
were randomized to knowledge and 269 to no knowledge of FFN.
Settings
All trials were based in hospital settings. One trial took place in
the United Kingdom (Dutta 2011); all the other trials took place
in the United States. Dutta 2011 and Plaut 2003 were multicenter
and the remaining four trials were based in single hospitals.
Participants
All trials included women with singleton gestations and threat-
ened PTL from around 23 to around 35 weeks’ gestation. All the
trials excluded multiple pregnancies apart from Plaut 2003. We
requested patient-level databases from all authors, and obtained
them from Grobman 2004, Lee 2013, Lowe 2004, and Nguyen
2002. Dutta 2011 and Plaut 2003 also replied to our query, but
had no additional data to what they had already published. Our
analysis was based only on singleton gestations. We avoided re-
peated entries of the same patients, which was possible since we
had patient-level data for the one trial where this occurred (Plaut
2003).
Interventions and comparisons
Of 546 women, 277 were randomized to knowledge of FFN and
269 to no knowledge of FFN. Intervention groups had the FFN
following signs of PTL. Time taken to obtain results was not re-
ported in most trials. In Lowe 2004, it took less than one hour,
and Plaut 2003 took between one and two hours. Dutta 2011
and Nguyen 2002 did not perform FFN on women in the con-
trol group. The other trials performed FFN on participants in the
control group but did not disclose the results. Only Lee 2013 and
Nguyen 2002 had a protocol for positive FFN tests.
Funding
Two trials were supported by affiliated universities (Dutta 2011;
Lowe 2004), and two trials did not disclose their funding sources
(Lee 2013;Nguyen 2002). Two were sponsored by Adeza Biomed-
ical which produced the FFN tests used in the trials (Grobman
2004; Plaut 2003).
Declarations of interest
Dutta 2011 and Lee 2013 declared that no authors had any con-
flicts of interest. None of the other trials reported whether or not
there were conflicts of interest.
Excluded studies
We excluded seven of the 11 excluded studies because they
only included women with positive (six trials) (Andrews 2001;
Bisits 2004; Goldenberg 2001; Hauth 2001; ISRCTN43735180;
Shennan 2006) or only with negative (one trial) (Elliott 2005)
FFN results. One excluded study (Kalchbrenner 1999) compared
speculum versus digital collection of FFN, with no management
reported based on FFN results. Another study was excluded be-
cause it used different diagnostic tests, and only partly used FFN
(Gallot 2018) and one study was published only as an abstract
with insufficient information provided to judge the quality and
risk of bias (Osório 2010). Another excluded study used mainly
transvaginal ultrasound cervical length, and not FFN, in the algo-
rithm studied (Ness 2007).
Risk of bias in included studies
See Figure 2; Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Risk of selection bias was considered low in four of the six included
trials. These four trials used computer-generated random sequence
generation and sealed opaque envelopes to conceal allocation (
Grobman 2004; Lee 2013; Lowe 2004; Plaut 2003). One study
(Dutta 2011) used telephonic random number generation but did
not describe allocation concealment. The sixth study (Nguyen
2002) did not describe random sequence generation or allocation
concealment (only the abstract of this study has been published).
Blinding
Women and staff were aware of the intervention they were allo-
cated to due to its nature but it is unclear if this affected results.
Laboratory personnel who performed the FFN test were blinded
to women’s characteristics and outcomes in Grobman 2004, Lee
2013, and Plaut 2003. One trial was unblinded (Lowe 2004). It
was unclear in the remaining trials whether outcome assessors were
blinded.
Incomplete outcome data
Two studies were assessed as having low risk of attrition bias be-
cause they reported no loss to follow-up (Grobman 2004; Lee
2013). In the remaining four trials, there was insufficient detail in
the reports to permit a judgement of low or high risk and so these
trials were assessed as being at unclear risk (Dutta 2011; Lowe
2004; Nguyen 2002; Plaut 2003). See Characteristics of included
studies for further details.
Selective reporting
Risk of reporting bias was considered low in five of the six included
studies; no deviations from original protocols were noted. The
sixth study (Nguyen 2002) did not describe reporting details (only
the abstract of this study has been published).
Other potential sources of bias
The included studies did not have enough information to ade-
quately assess the presence of other forms of bias and, as such,
were deemed to have an unclear risk of bias. Nguyen 2002 was
published only as abstract. Two studies (Grobman 2004; Plaut
2003) were sponsored by Adeza Biomedical which manufactures
the FFN tests, however the results from these studies did not seem
to be skewed favourably toward the FFN tests.
Effects of interventions
See: Summary of findings for the main comparison Main
comparison (FFN knowledge versus no knowledge)
See: Summary of findings for the main comparison the compar-
ison (i.e. FFN knowledge versus no knowledge) and for selected
important outcomes, we graded the quality of the evidence and
created ’Summary of findings’ tables. For all these outcomes, the
evidence was graded as mainly low quality due to the imprecision
of effect estimates, limitations in study design, and inconsistency
of results.
We included six trials (involving 546 women) in this review. All
women included had singleton gestations and threatened PTL.
Fetal fibronectin knowledge versus no knowledge
Primary outcome
Preterm birth before 37 weeks appeared to favour management
based on knowledge of FFN results (20.7%) compared to controls
without such knowledge (29.2%) though the confidence intervals
(CIs) just crossed the line of no effect so we could not be certain
of this effect (risk ratio (RR) 0.72, 95% CI 0.52 to 1.01; 5 trials;
434 women; low-quality evidence; Analysis 1.1). Three out of five
trials had RRs less than one, with no heterogeneity.
We performed a sensitivity analysis for the primary outcome, by
removing Nguyen 2002 which was assessed to be at unclear risk
of allocation concealment. Removing this data from the analysis
indicated that knowledge of FFN may result in fewer preterm
births before 37weeks (19.4% compared to 29.9%) withCI below
the line of no effect (RR 0.67, 95% CI 0.46 to 0.97; 4 trials; 357
women; Analysis 2.1).
Secondary outcomes
Effects on other secondary outcomes are uncertain due to serious
concerns in study design, inconsistency, and imprecision of effect
estimates:
• preterm birth less than 34 weeks (RR 1.09, 95% CI 0.54 to
2.18; 4 trials; 357 women; low-quality evidence; Analysis 1.2)
• preterm birth less than 32 weeks (average RR 0.79, 95% CI
0.16 to 3.96; 4 trials; 357 women; Tau² = 0.93; I² = 46%; very-
low quality evidence; Analysis 1.3)
• preterm birth less than 28 weeks (RR 0.63, 95% CI 0.15 to
2.59; 4 trials; 357 women; Analysis 1.4)
• gestational age at delivery (weeks) (mean difference (MD)
0.14, 95% CI -0.36 to 0.63; 5 trials; 456 neonates; Analysis 1.5)
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• birthweight less than 2500 g (no events in either group; one
trial; 68 neonates; Analysis 1.6)
• perinatal death (RR 2.21, 95% CI 0.09 to 52.27; 2 trials;
164 neonates; Analysis 1.7)
• maternal hospitalization (RR 1.06, 95% CI 0.79 to 1.43; 5
trials; 441 women; low-quality evidence; Analysis 1.8)
• tocolysis (RR 0.97, 95% CI 0.75 to 1.24; 6 trials; 531
women; Analysis 1.9)
• steroids for fetal lung maturity (RR 1.04, 95% CI 0.79 to
1.38; 5 trials; 441 neonates; Analysis 1.10)
• time to evaluate (time from arrival to hospital for evaluation
of PTL to decision regarding admission, discharge, or extended
monitoring (hours)) (MD 0.55, 95% CI -0.39 to 1.50; random-
effects; 6 trials; 528 women; Tau² = 0.55; I² = 52%; Analysis
1.11)
• respiratory distress syndrome (RR 0.91, 95% CI 0.06 to
14.06; 2 trials; 148 neonates; Analysis 1.12)
• NICU admission (RR 2.36, 95% CI 0.92 to 6.07; 2 trials;
124 neonates; Analysis 1.13)
• economic analysis (hospitalization charges): Nguyen 2002
reported data regarding hospitalization charges and found that
management based on FFN test required higher hospitalization
charges (US dollars) (MD 153.00, 95% CI 24.01 to 281.99;
Analysis 1.14).
Intraventricular haemorrhage, necrotizing enterocolitis, sepsis,
NICU days, and maternal well-being were not reported in any
trial.
D I S C U S S I O N
Summary of main results
Management based on knowledge of FFN results may reduce
preterm birth before 37 weeks (21.6%) versus controls without
such knowledge (29.2%).However,management based on knowl-
edge of FFN results may make little or no difference to preterm
birth before 34 weeks or maternal hospitalization. The evidence
for preterm birth before 32 weeks is uncertain because the quality
was found to be very low.
For all other outcomes, for which there were available data
(preterm birth less than 28 weeks; gestational age at delivery
(weeks); birthweight less than 2500 g; perinatal death; tocolysis;
steroids for fetal lung maturity; time to evaluate; respiratory dis-
tress syndrome; neonatal intensive care unit (NICU) admission;
and NICU days), knowledge of FFN results may make little or no
difference to the outcomes.
Therefore, further research is necessary before fetal fibronectin test-
ing can be routinely recommended. There are no randomized tri-
als comparing knowledge versus no knowledge of fetal fibronectin
in asymptomatic pregnant women, or in women with multiple
gestations.
Overall completeness and applicability of
evidence
We attempted to be as inclusive as possible in the search strategy.
Nonetheless, the studies reported are predominantly from the US,
whichmay limit the external validity of these results. The evidence
from the included studies is also based on the cutoff for the fFN
bedside test, also known as Quickchack fFN (50 ng/L). It should
be noted, that the use of quantitative fFN which has since become
available, may affect any future conclusions of this review.
It is still unclear which interventions are most beneficial once fe-
tal fibronectin results are known. The Ness positive study (Ness
2007) reported a detailed protocol of management based on cer-
vical length mainly (and fetal fibronectin results for a small sub-
group), and could be replicated in further research trials. Our re-
view did not include by design assessment of effectiveness of in-
terventions based on positive fetal fibronectin testing, or negative
fetal fibronectin testing.We identified no trials on women without
signs or symptoms of labor.
Quality of the evidence
For the main comparison (fetal fibronectin knowledge versus no
knowledge) and for most important outcomes (preterm birth less
than 37 weeks; preterm birth less than 34 weeks; preterm birth less
than 32 weeks; maternal hospitalization), we graded the quality
of evidence using the GRADE approach. For most of these out-
comes, the evidence was graded as low-quality mainly due to the
imprecision of effect estimates and limitations in study design. We
graded preterm birth less than 32 weeks as very low-quality due
to evidence of inconsistency in results, in addition to imprecision
of effect estimates and limitations in study design (Summary of
findings for the main comparison).
Potential biases in the review process
We acknowledge that our analysis of preterm delivery is flawed
as it was analyzed as four separate outcomes (< 37, < 34, < 32,
< 28 weeks); and clearly these outcomes are not independent.
A much better analysis would be to use the time to birth for
each participant, but that would require individual patient data
(IPD). This approach is not feasible without the availability of
IPD. Vincenzo Berghella is a co-author on one of the excluded
trials (Ness 2007) andwas not involved in the eligibility assessment
for this trial as this was assessed by Gabriele Saccone.
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Agreements and disagreements with other
studies or reviews
The findings of this review largely agree with our prior Cochrane
Review andother reviews on this topic, with nowadditional studies
and larger sample size (Berghella 2008; Berghella 2016).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from this review suggests that management based
on knowledge of FFN results may reduce preterm birth before
37 weeks. However, our confidence in this result is limited as the
evidence was found to be of low-quality. Effects on other substan-
tive outcomes are uncertain due to serious concerns in study de-
sign, inconsistency, and imprecision of effect estimates. No trials
were identified on asymptomatic women, or multiple gestations.
Currently, the only management protocol for screening of women
with threatened preterm labor shown by randomized trial data to
decrease preterm birth has been that based mainly on transvaginal
ultrasound cervical length, with fetal fibronectin only in women
with cervical length 20 mm to 29 mm (Berghella 2016; Ness
2007).
Implications for research
Given that the evidence suggests that there may be a reduction of
around 28% in the primary outcome, further research could be en-
couraged, minimizing attrition bias, to better understand whether
and under what circumstances the predictive characteristics of the
fetal fibronectin test can be translated into better clinical manage-
ment. Future studies could include specific populations (e.g. sin-
gleton gestations with symptoms of preterm labor), a study group
managed with a protocol based on the fetal fibronectin results, and
report not only maternal but also significant perinatal outcomes.
Cost-effectiveness analyses are also needed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dutta 2011
Methods Randomized controlled trial
Participants 24 0/7-34 6/7 weeks singletons presenting to the hospital for the primary reason of
uterine activity. Twins excluded. Number of participants = 93 (100 enrolled, but 7
excluded because they did not meet the inclusion criteria of which 4 were twins)
Interventions FFN testing (44) versus no testing (44)
Time FFN results available: unknown
Protocol for FFN knowledge group: no
Outcomes Primary: hospital admission
Notes Unpublished data were not obtainable.
Setting: 2 hospitals, Scotland
Dates: December 2007 - March 2009
Conflict of interest: none
Funding source: the trial is registered with the University of Edinburgh which is a
charitable body, registered in Scotland, with registration number SC005336
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Telephonic randomization
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is reported that those that did not follow the protocol
were excluded from the study. No study flow diagram.
In methods reports that 100 patients were enrolled, and
93 were available for analysis - 44 in the control group
and 49 in the test group - but then denominator results
differ - sometimes both groups reported as 44 and then
in other places reports 49
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Dutta 2011 (Continued)
Selective reporting (reporting bias) Low risk The trial was registered and therewere nodeviations from
the original protocol in the final publication
Other bias Unclear risk Insufficient reporting to determine presence of other
form of bias
Grobman 2004
Methods Randomized controlled trial
Participants 24-34 week singletons with > 6 contractions/hour. Twins excluded
Number of participants: 100 (50/50: knowledge/no knowledge)
Interventions FFN knowledge or not
Time FFN results available: unknown
Protocol for FFN knowledge group: no
Outcomes Primary: total costs
Notes Intention-to-treat; only singletons; no protocol
Positive FFN test in each group: 5 (10%) in knowledge, 3 (6%) in no knowledge group
Setting: hospital, United States
Dates: “12 month period” dates unclear
Conflict of interest: not mentioned
Funding source: supported by a grant from Adeza Biomedical, Sunnyvale, Calif
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Computer-generated, opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory personnel who performed the FFN test were
blinded to women’s characteristics and outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up. One woman randomized to the
knowledge group - her results were not available because
of problems with the machine - however it is reported
that outcomes for this patient were analysed in the group
to which she was randomized, suggesting they adhered
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Grobman 2004 (Continued)
to intention to treat analysis
Selective reporting (reporting bias) Low risk The trial was registered and therewere nodeviations from
the original protocol in the final publication
Other bias Unclear risk Insufficient reporting to determine presence of other
form of bias
Lee 2013
Methods Randomized controlled trial
Participants 24 0/7-33 6/7 weeks singletons with symptoms suggesting PTL
Number of participants: 76 (44/32: knowledge/no knowledge)
Interventions FFN knowledge versus no FFN knowledge
Time FFN results available: unknown
Protocol for FFN knowledge group: yes
Outcomes Time required to evaluate participants in triage in Labor and Delivery
Notes Setting: medical centre, United States
Dates: September 2006 - December 2010
Conflict of interest: none
Funding source: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Computer-generated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory personnel who performed the FFN test were
blinded to women’s characteristics and outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Low risk The trial was registered and therewere nodeviations from
the original protocol in the final publication
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Lee 2013 (Continued)
Other bias Unclear risk Insufficient reporting to determine presence of other
form of bias
Lowe 2004
Methods Randomized controlled trial
Participants 23-34 week singletons/twins with contractions +/- cervical change
Number of participants: 97 [89 singletons/8 twins] (46/51: knowledge/no knowledge)
Interventions FFN knowledge or not
Time FFN results available: < 1 hour
Protocol for FFN knowledge group: no
Outcomes Primary: length of stay
Notes 13/110 excluded post-randomization: unclear whether intention-to-treat; included
twins; no protocol
Positive FFN test in each group: 11 (24%) in knowledge group; FFN test not performed
in no knowledge group
Setting: hospital, United States
Dates: August 2000 - May 2002
Conflict of interest: not mentioned
Funding source: supported by Process Improvement Grant, University of Iowa
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Computer-generated, opaque envelopes, blocks of 10
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unblinded intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 110 were enrolled into the study, but 13 were not in-
cluded (reasons were documented - but did not present
characteristics of these women or make it clear which
group they had been randomized to) and so 97 women
were available for the analysis. It is not clear exactly how
many were initially randomised
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Lowe 2004 (Continued)
Selective reporting (reporting bias) Low risk No deviation from the original protocol
Other bias Unclear risk Insufficient reporting to determine presence of other
form of bias
Nguyen 2002
Methods Randomized controlled trial
Participants 24-35 weeks (unclear if twins included) with symptoms of PTL
Number of participants: 77 (42/35: knowledge/no knowledge)
Interventions FFN testing done (and knowledge available) versus not done (so knowledge not available)
Time FFN results available: unknown
Protocol for FFN knowledge group: yes
Outcomes Primary: cost-effectiveness
Notes Abstract only; unclear if intention-to-treat, twins included, protocol, etc
Positive FFN test in each group: not available in knowledge group; FFN not performed
in no knowledge group
Setting: hospital, United States
Dates: not specified
Conflict of interest: not mentioned
Funding source: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description available (only abstract published)
Allocation concealment (selection bias) Unclear risk No description available (only abstract published)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No description available (only abstract published)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No description available (only abstract published)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only abstract available - all enrolled appear to have been
randomized
Selective reporting (reporting bias) Unclear risk No protocol available
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Nguyen 2002 (Continued)
Other bias Unclear risk No description available (only abstract published)
Plaut 2003
Methods Randomized controlled trial
Participants 24-34 6/7 week singletons/twins with ’symptoms of PTL’
Number of participants: 114 (unclear from text) randomized [96 singleton, 12 twins]
(analysed: 51/57: knowledge/no knowledge)
Interventions FFN knowledge or not
Time FFN results available: 1-2 hours
Protocol for FFN knowledge group: no
Outcomes Primary: transport rates (not reported)
Notes 6/114 excluded post-randomization: not intention-to-treat - 6 patients were excluded;
8 participants entered in study twice; stopped trial prematurely; sponsored by Adeza;
included twins; no protocol
Positive FFN test in each group: 6 (12%) in knowledge, 6 (10.5%) in no knowledge
group
Setting: 4 community hospitals, United States
Dates: September 2000 - December 2001
Conflict of interest: not mentioned
Funding source: supported by Adeza Biomedical, Sunnyvale, Calif
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Computerized opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory personnel who performed the FFN test were
blinded to women’s characteristics and outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Consent obtained from 114 patients, 6 patients were ex-
cluded (reasons given), this left 108 swabs from 100 dif-
ferent patients - 8 patients were entered into the study
twice. Results are presented for 108 swabs. Not clear
number originally randomized into each group
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Plaut 2003 (Continued)
Selective reporting (reporting bias) Low risk No deviation from the original protocol
Other bias Unclear risk Insufficient reporting to determine presence of other
form of bias
FFN: fetal fibronectin
ITT: intention to treat
PTL: preterm labor
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrews 2001 Only women with positive FFN were included.
Bisits 2004 Only women with positive FFN were included. They were randomized to tocolysis or not
Elliott 2005 Only women with negative FFN were included.
Gallot 2018 Registration protocol of a trial using different diagnostic tests, and only in part on FFN
Goldenberg 2001 Only women with positive FFN were included (secondary analysis of NICHD BV/TV study)
Hauth 2001 Only women with positive FFN were included.
ISRCTN43735180 Only women with positive FFN were included.
Kalchbrenner 1999 This was a trial comparing speculum versus digital collection of FFN. There were no data regarding the results
of the FFN test, and no intervention was reported based on FFN results
Ness 2007 The algorithm used was based mostly on cervical length results, and only in part (for cervical lengths 20-29
mm) on FFN
Osório 2010 Published only as abstract with no data available on methods or the outcomes of interest
Shennan 2006 Only women with positive FFN were included.
FFN: fetal fibronectin
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Characteristics of ongoing studies [ordered by study ID]
NCT01431885
Trial name or title 2 methods of diagnosing preterm labor
Methods Randomized controlled trial
Participants Symptomatic women with more than 6 uterine contractions per hour
Interventions Symptomatic preterm labor patients will be randomized to diagnosis of preterm labor by serial digital exami-
nation versus an algorithm incorporating transvaginal ultrasound measurement of cervical length and vaginal
fetal fibronectin
Outcomes Preterm birth < 37 weeks
Starting date 2011
Contact information Conrad Chao; 001-559-499-6548; cchao@fresno.ucsf.edu
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. FFN knowledge versus no knowledge
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Preterm birth < 37 weeks 5 434 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.52, 1.01]
2 Preterm birth < 34 weeks 4 357 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.54, 2.18]
3 Preterm birth < 32 weeks 4 357 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.16, 3.96]
4 Preterm birth < 28 weeks 4 357 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.15, 2.59]
5 Gestational age at delivery 5 456 Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.36, 0.63]
6 Birthweight < 2500 g 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Perinatal death (fetal death and
neonatal death)
2 164 Risk Ratio (M-H, Fixed, 95% CI) 2.21 [0.09, 52.27]
8 Maternal hospitalization 5 441 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.79, 1.43]
9 Tocolysis 6 531 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.75, 1.24]
10 Steroids for fetal lung maturity 5 441 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.79, 1.38]
11 Time to evaluate 6 528 Mean Difference (IV, Random, 95% CI) 0.55 [-0.39, 1.50]
12 Respiratory distress syndrome 2 148 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.06, 14.06]
13 Neonatal intensive care unit
admission
2 124 Risk Ratio (M-H, Fixed, 95% CI) 2.36 [0.92, 6.07]
14 Economic analysis
(hospitalization charges)
1 77 Mean Difference (IV, Fixed, 95% CI) 153.0 [24.01, 281.
99]
Comparison 2. FFN knowledge versus no knowledge: sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Preterm birth < 37 weeks 4 357 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.46, 0.97]
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Analysis 1.1. Comparison 1 FFN knowledge versus no knowledge, Outcome 1 Preterm birth < 37 weeks.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 1 Preterm birth < 37 weeks
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nguyen 2002 11/42 9/35 15.9 % 1.02 [ 0.48, 2.17 ]
Plaut 2003 5/43 12/47 18.6 % 0.46 [ 0.17, 1.19 ]
Grobman 2004 10/50 13/50 21.1 % 0.77 [ 0.37, 1.59 ]
Lowe 2004 13/46 24/51 36.9 % 0.60 [ 0.35, 1.04 ]
Lee 2013 7/41 4/29 7.6 % 1.24 [ 0.40, 3.84 ]
Total (95% CI) 222 212 100.0 % 0.72 [ 0.52, 1.01 ]
Total events: 46 (FFN), 62 (Control)
Heterogeneity: Chi2 = 3.02, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.2. Comparison 1 FFN knowledge versus no knowledge, Outcome 2 Preterm birth < 34 weeks.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 2 Preterm birth < 34 weeks
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Plaut 2003 2/43 2/47 13.6 % 1.09 [ 0.16, 7.42 ]
Grobman 2004 5/50 3/50 21.4 % 1.67 [ 0.42, 6.60 ]
Lowe 2004 5/46 9/51 60.8 % 0.62 [ 0.22, 1.70 ]
Lee 2013 3/41 0/29 4.2 % 5.00 [ 0.27, 93.26 ]
Total (95% CI) 180 177 100.0 % 1.09 [ 0.54, 2.18 ]
Total events: 15 (FFN), 14 (Control)
Heterogeneity: Chi2 = 2.61, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.3. Comparison 1 FFN knowledge versus no knowledge, Outcome 3 Preterm birth < 32 weeks.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 3 Preterm birth < 32 weeks
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Plaut 2003 2/43 1/47 28.1 % 2.19 [ 0.21, 23.26 ]
Lowe 2004 1/46 7/51 33.0 % 0.16 [ 0.02, 1.24 ]
Grobman 2004 3/50 2/50 38.9 % 1.50 [ 0.26, 8.60 ]
Lee 2013 0/41 0/29 Not estimable
Total (95% CI) 180 177 100.0 % 0.79 [ 0.16, 3.96 ]
Total events: 6 (FFN), 10 (Control)
Heterogeneity: Tau2 = 0.93; Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.4. Comparison 1 FFN knowledge versus no knowledge, Outcome 4 Preterm birth < 28 weeks.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 4 Preterm birth < 28 weeks
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Plaut 2003 0/43 1/47 29.5 % 0.36 [ 0.02, 8.70 ]
Lowe 2004 0/46 1/51 29.3 % 0.37 [ 0.02, 8.83 ]
Grobman 2004 2/50 2/50 41.2 % 1.00 [ 0.15, 6.82 ]
Lee 2013 0/41 0/29 Not estimable
Total (95% CI) 180 177 100.0 % 0.63 [ 0.15, 2.59 ]
Total events: 2 (FFN), 4 (Control)
Heterogeneity: Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.5. Comparison 1 FFN knowledge versus no knowledge, Outcome 5 Gestational age at delivery.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 5 Gestational age at delivery
Study or subgroup FFN Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Plaut 2003 51 29.9 (3.2) 57 30.4 (2.7) 19.3 % -0.50 [ -1.62, 0.62 ]
Lowe 2004 46 38.3 (2.8) 51 37.4 (3.4) 16.0 % 0.90 [ -0.34, 2.14 ]
Grobman 2004 50 38 (3) 50 38 (3) 17.6 % 0.0 [ -1.18, 1.18 ]
Dutta 2011 43 38.07 (3.25) 38 38.09 (2.33) 16.4 % -0.02 [ -1.24, 1.20 ]
Lee 2013 41 38.6 (2.1) 29 38.3 (1.7) 30.7 % 0.30 [ -0.59, 1.19 ]
Total (95% CI) 231 225 100.0 % 0.14 [ -0.36, 0.63 ]
Heterogeneity: Chi2 = 2.94, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [FFN knowledge] Favours [No knowledge]
Analysis 1.6. Comparison 1 FFN knowledge versus no knowledge, Outcome 6 Birthweight < 2500 g.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 6 Birthweight < 2500 g
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lee 2013 0/39 0/29 Not estimable
Total (95% CI) 39 29 Not estimable
Total events: 0 (FFN), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.7. Comparison 1 FFN knowledge versus no knowledge, Outcome 7 Perinatal death (fetal death
and neonatal death).
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 7 Perinatal death (fetal death and neonatal death)
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Grobman 2004 0/50 0/50 Not estimable
Lee 2013 1/37 0/27 100.0 % 2.21 [ 0.09, 52.27 ]
Total (95% CI) 87 77 100.0 % 2.21 [ 0.09, 52.27 ]
Total events: 1 (FFN), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.8. Comparison 1 FFN knowledge versus no knowledge, Outcome 8 Maternal hospitalization.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 8 Maternal hospitalization
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nguyen 2002 9/42 7/35 13.3 % 1.07 [ 0.44, 2.58 ]
Lowe 2004 16/46 12/51 19.8 % 1.48 [ 0.78, 2.79 ]
Grobman 2004 13/50 14/50 24.3 % 0.93 [ 0.49, 1.77 ]
Dutta 2011 21/46 22/45 38.6 % 0.93 [ 0.60, 1.44 ]
Lee 2013 3/44 2/32 4.0 % 1.09 [ 0.19, 6.16 ]
Total (95% CI) 228 213 100.0 % 1.06 [ 0.79, 1.43 ]
Total events: 62 (FFN), 57 (Control)
Heterogeneity: Chi2 = 1.55, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.9. Comparison 1 FFN knowledge versus no knowledge, Outcome 9 Tocolysis.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 9 Tocolysis
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nguyen 2002 7/42 7/35 10.7 % 0.83 [ 0.32, 2.15 ]
Plaut 2003 25/43 28/47 37.4 % 0.98 [ 0.69, 1.38 ]
Grobman 2004 8/50 9/50 12.6 % 0.89 [ 0.37, 2.12 ]
Lowe 2004 22/46 23/51 30.5 % 1.06 [ 0.69, 1.63 ]
Dutta 2011 3/46 4/45 5.7 % 0.73 [ 0.17, 3.09 ]
Lee 2013 3/44 2/32 3.2 % 1.09 [ 0.19, 6.16 ]
Total (95% CI) 271 260 100.0 % 0.97 [ 0.75, 1.24 ]
Total events: 68 (FFN), 73 (Control)
Heterogeneity: Chi2 = 0.48, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.10. Comparison 1 FFN knowledge versus no knowledge, Outcome 10 Steroids for fetal lung
maturity.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 10 Steroids for fetal lung maturity
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nguyen 2002 9/42 7/35 12.3 % 1.07 [ 0.44, 2.58 ]
Lowe 2004 23/46 22/51 33.6 % 1.16 [ 0.76, 1.78 ]
Grobman 2004 8/50 10/50 16.1 % 0.80 [ 0.34, 1.86 ]
Lee 2013 9/44 2/32 3.7 % 3.27 [ 0.76, 14.13 ]
Dutta 2011 17/46 21/45 34.2 % 0.79 [ 0.49, 1.29 ]
Total (95% CI) 228 213 100.0 % 1.04 [ 0.79, 1.38 ]
Total events: 66 (FFN), 62 (Control)
Heterogeneity: Chi2 = 4.18, df = 4 (P = 0.38); I2 =4%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours [FFN knowledge] Favours [No knowledge]
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Analysis 1.11. Comparison 1 FFN knowledge versus no knowledge, Outcome 11 Time to evaluate.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 11 Time to evaluate
Study or subgroup FFN Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nguyen 2002 42 3.3 (1.7) 35 2.7 (1.7) 33.3 % 0.60 [ -0.16, 1.36 ]
Plaut 2003 43 6.3 (8) 47 10 (27.1) 1.3 % -3.70 [ -11.81, 4.41 ]
Grobman 2004 50 4.12 (3.59) 50 4.49 (3.9) 21.0 % -0.37 [ -1.84, 1.10 ]
Lowe 2004 46 16 (7.4) 51 12 (4.9) 10.5 % 4.00 [ 1.47, 6.53 ]
Dutta 2011 44 16.8 (25.3) 44 17.7 (25.5) 0.8 % -0.90 [ -11.51, 9.71 ]
Lee 2013 44 3 (1.8) 32 2.8 (1.6) 33.1 % 0.20 [ -0.57, 0.97 ]
Total (95% CI) 269 259 100.0 % 0.55 [ -0.39, 1.50 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 10.40, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 FFN knowledge versus no knowledge, Outcome 12 Respiratory distress
syndrome.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 12 Respiratory distress syndrome
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dutta 2011 1/44 1/40 100.0 % 0.91 [ 0.06, 14.06 ]
Lee 2013 0/37 0/27 Not estimable
Total (95% CI) 81 67 100.0 % 0.91 [ 0.06, 14.06 ]
Total events: 1 (FFN), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 FFN knowledge versus no knowledge, Outcome 13 Neonatal intensive care
unit admission.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 13 Neonatal intensive care unit admission
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dutta 2011 10/30 3/30 56.5 % 3.33 [ 1.02, 10.92 ]
Lee 2013 3/37 2/27 43.5 % 1.09 [ 0.20, 6.11 ]
Total (95% CI) 67 57 100.0 % 2.36 [ 0.92, 6.07 ]
Total events: 13 (FFN), 5 (Control)
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 FFN knowledge versus no knowledge, Outcome 14 Economic analysis
(hospitalization charges).
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 1 FFN knowledge versus no knowledge
Outcome: 14 Economic analysis (hospitalization charges)
Study or subgroup FFN Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nguyen 2002 42 452 (381) 35 299 (175) 100.0 % 153.00 [ 24.01, 281.99 ]
Total (95% CI) 42 35 100.0 % 153.00 [ 24.01, 281.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 FFN knowledge versus no knowledge: sensitivity analysis, Outcome 1 Preterm
birth < 37 weeks.
Review: Fetal fibronectin testing for reducing the risk of preterm birth
Comparison: 2 FFN knowledge versus no knowledge: sensitivity analysis
Outcome: 1 Preterm birth < 37 weeks
Study or subgroup FFN Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Plaut 2003 5/43 12/47 22.1 % 0.46 [ 0.17, 1.19 ]
Grobman 2004 10/50 13/50 25.0 % 0.77 [ 0.37, 1.59 ]
Lowe 2004 13/46 24/51 43.8 % 0.60 [ 0.35, 1.04 ]
Lee 2013 7/41 4/29 9.0 % 1.24 [ 0.40, 3.84 ]
Total (95% CI) 180 177 100.0 % 0.67 [ 0.46, 0.97 ]
Total events: 35 (FFN), 53 (Control)
Heterogeneity: Chi2 = 2.05, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search methods for ICTRP, ClinicalTrials.gov and additional MEDLINE search
ICTRP
fetal AND fibronectin
ffn
ClinicalTrials.gov
fibronectin | Interventional Studies | pregnancy
fibronectin | Interventional Studies | preterm
Interventinal Studies | preterm | Fetal fibronectin
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WH A T ’ S N E W
Date Event Description
7 September 2018 New search has been performed Search updated and new trials added. A ’Summary of
findings’ table has been incorporated
7 September 2018 New citation required but conclusions have not
changed
Two new studies have been added (Dutta 2011; Lee
2013), but the conclusions have not changed.
H I S T O R Y
Protocol first published: Issue 4, 2007
Review first published: Issue 4, 2008
Date Event Description
16 December 2007 Amended Converted to new review format.
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S O U R C E S O F S U P P O R T
Internal sources
• None, Other.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
A ’Summary of findings’ table has been incorporated in this update and we added in a search of ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform ( ICTRP) for unpublished, planned, and ongoing trial reports.
In the original review, we also ran a separate search of MEDLINE (January 1966 to December 2007) using the search strategy detailed
below:
MEDLINE
#1 exp Obstetric labor, premature/
#2 Fibronectins/
#3 #1 and #2
#4 fetal adj3 fibronectin
#5 #3 or #4
I N D E X T E R M S
Medical Subject Headings (MeSH)
Biomarkers [analysis]; Fetus; Fibronectins [∗analysis]; Premature Birth [∗prevention & control]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Pregnancy
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